We believe that our findings support a rationale for clinical trials testing anti-angiogenic agents (e.g., Bevacizumab) in combination with anti-PD1 therapy (e.g., Pembrolizumab) in VEGFA-high melanoma patients. Here, PDCD1 is linked to melanoma.